This is a preview of subscription content, log in via an institution to check access.
Notes
2019 US dollars
Reference
Schulz BG, et al. Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis Journal of Managed Care and Specialty Pharmacy 27: No. 11, Nov 2021. Available from: URL: https://doi.org/10.18553/jmcp.2021.27.11.1592
Rights and permissions
About this article
Cite this article
Vedolizumab cost effective versus adalimumab for ulcerative colitis. PharmacoEcon Outcomes News 891, 30 (2021). https://doi.org/10.1007/s40274-021-08188-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08188-7